RxDoctor Payments Data

Matthew Williams, MD

Internal Medicine · Springfield, MONPI 1184121998

Payments from drug & device makers

$1,128in general payments, 2019–2025

Across 24 payments — averaging $47.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$238
  • Lilly USA, LLC$204
  • Idorsia Pharmaceuticals US Inc$125
  • Boston Scientific$123
  • Boehringer Ingelheim$108
  • Amgen$94
  • plus $237 from 8 others

What the payments were for

  • Food & beverage$1,128100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,128 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$122,585
Medicare patients
303
Services billed
2,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide202$215,764
OzempicSemaglutide165$192,841
JardianceEmpagliflozin198$184,928
EliquisApixaban99$104,947
XareltoRivaroxaban109$98,255
Repatha SureclickEvolocumab88$67,423
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$51,216
JanuviaSitagliptin Phosphate61$48,277
XifaxanRifaximin12$45,492
TrulicityDulaglutide33$37,569
SymbicortBudesonide/Formoterol Fumarate67$18,862
EntrestoSacubitril/Valsartan11$15,381
Xultophy 100-3.6Insulin Degludec/Liraglutide12$14,482
TrintellixVortioxetine Hydrobromide27$13,147
ArexvyRsvpref3 Antigen/As01e/Pf45$12,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$204$253,333235 claims
Novo NordiskOzempic, Xultophy 100-3.6$18$207,323177 claims
Boehringer IngelheimJardiance$108$184,928198 claims
Johnson & JohnsonXarelto$238$98,255109 claims
AstraZenecaSymbicort, Farxiga$87$27,43179 claims
NovartisEntresto$17$15,38111 claims
AbbVieSynthroid$32$2,32028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →